Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival
Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response
FDA Grants Accelerated Approval to Imbruvica
Two Papers Evaluate CyberKnife Survival Rates and Tolerability
ANG1005 Demonstrates Activity In Patients with Brain Metastases
MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues
AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial
NCI CTEP Approved Trials For the Month of November
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.